Account
Case Study Icon
Case Studies

Securing reimbursement for an orphan drug via NICE highly specialised technology route to enable UK patient access

01/01/2023

Author:

Sarah Bailey
About the Author

Article Tags

HTA HTA Process NICE Orphan Drugs Pricing

Share this article

Related articles

17.03.2025
Protected: Presentation: How to navigate early pay...

There is no excerpt because this is a protected post.

Read more
Articles
17.03.2025
PICO and Mix: What the PICO exercises mean for JCA...

The population, intervention, comparator, and outcomes (PICO) element of the upcoming EU Joint Clini...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch